Marijuana. DATE: June 26, 2018 PRESENTED BY: Melissa Weimer, DO, MCR, FASAM

Similar documents
Marijuana. DATE: February 21, 2017 PRESENTED BY: Melissa Weimer, DO, Assistant Professor of Medicine

Medications For Alcohol Use Disorder

Basics of Benzodiazepine Use Disorder. DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR

Marijuana and the Chronic Non-Cancer Pain Patient

Acknowledgements: What it is What it s not. Cannabis Evidence Series. Evidence-informed decision-making

Treating a Patient with Cannabis Use Disorder. Disclosures. Three Areas of Focus 4/9/2018. Grants from NIDA, World Health Organization.

Medical Marijuana Martin P. Eason MD, JD Associate Chief of Staff for Education Mountain Home VA Medical Center. Disclosure.

Marijuana and Adolescents: Truth and Consequences. Disclosure Statement OBJECTIVES. Secondary Objectives. State of Marijuana in US

Medical Cannabis MATT WEBSTER DO, MS

POLICY NUMBER: POL 153

CDHA 2016 Fall Symposium. Speaker Handout Files. For registered attendees only

Consumer Information Cannabis (Marihuana, marijuana)

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St.

Cannabis Use: Scope of the Issue

4/15/2019. US States with Marijuana Laws in Have ACOG and SMFM taken notice? THE EFFECTS OF MARIJUANA USE ON PREGNANCY AND LACTATION

Health Impact of Cannabis: Adolescents

James McCormack BSc (Pharm), PharmD Professor Faculty of Pharmaceutical Sciences University of British Columbia Vancouver, BC, Canada

Dr. Meldon Kahan. Women s College Hospital. with PIA LAW

Medical Marijuana: The Move to Schedule II

Cannabis in the Community

Basics of Benzodiazepine Use Disorder. DATE: March 20, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR

AGENDA. 9:00 Sign-in and introductions 9:15 Marijuana 10:30 Break 10:45 Opioid Prevention 11:30 Discussion & Wrap-Up

This questionnaire will ask you about approved medical use of extracts and tinctures of cannabis at national level.

Frequently Asked Questions

CANNABIS FOR THE RHEUMATOLOGIST

PLENARY PANEL THE INTERSECTION OF MENTAL HEALTH AND MARIJUANA LEGALIZATION

9/28/2015. Support. R01CA A1 Intervening with smoking parents of inpatients to reduce

MARIJUANA & THE EFFECTS ON THE BRAIN

Medical Marijuana Update Chris Belletieri, DO

Medical Marijuana Consent Form

Co-Occurring Mental Health and Substance Use Disorders. DATE: 4/17/18 PRESENTED BY: John Mahan, MD

Outcome. Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana. Connie J. Cerilli, APRN, FNP-C

Educating Ohio Providers On The Basics Related To Recommending Medical Marijuana. Connie J. Cerilli, APRN, FNP-C

Doc, will you sign my medical. Fellow in Hematology/Medical Oncology General Internal Medicine Grand Rounds

Legalized Marijuana: Uses, Misuses & Abuses. Disclosures. Objectives. Kennon Heard University of Colorado SOM Dept Of Emergency Medicine

Puget Sound Educational Service District

MEDICAL MARIJUANA: WHAT S THE EVIDENCE?

A Conversation: Marijuana and Youth

Cannabis and What we Know. Bonnie Schnittker RN PHN Public Health Nurse October 20, 2017

WHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis. Expert Peer Review 2

Northern California Chapter, ACP Update In Medicine

Management of Marijuana Addiction

Opioid Review and MAT Clinic Marijuana

Marijuana and Adolescent Brain Development

Curious about Cannabis? Navigating the cannabis landscape in Pennsylvania LINDSEY MESTON, PHARMD ASHLEY FIRM, PHARMD

Medicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer

Pennsylvania House of Representatives. Joint Health and Judiciary Committee Hearing. Medical Cannabis - Health Care Forum

CANNABIS AND CANNABINOIDS: 2017 REPORT, U.S. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE

The Benefits and Harms of Cannabis Use in Chronic Pain or PTSD: A Systematic Review

Medical Cannabis: A Patient Primer

Federal Law: Marijuana

Cannabinoids: access and symptom management in cancer

Trends, Tactics and Toxicity: Marijuana Movement on Missouri College Campuses. Janice Putnam PhD, RN Amy Kiger MS, ABD Kelly Skinner DNP, FNP-C

Perkins Middle School

Medical Cannabis. Danial Schecter, MD, CCFP. Vocational Rehabilitation Association November 7th, Executive Director Cannabinoid Medical Clinic

A look at Marijuana in 2014

Marijuana as Medicine

The Sale of Cannabis in Pharmacies. Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association

Medical Cannabis and OMT

Use of Cannabinoids in Medical Practice

CANNABIS LEGALIZATION: SUPPORT MATERIAL FOR MANITOBA PHYSICIANS

Dr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina) S. Korownyk EDMONTON AB MEDICAL CANNABANOIDS IN PRIMARY CARE

The Shifting Federal Regulation of Cannabis Products

Cannabis Use Disorder: What Nurses Need to Know. Bari K Platter, MS, RN, PMHCNS-BC Clinical Nurse Specialist

INITIAL PATIENT INTAKE FORM

CANNABIS AND CANADA S CHILDREN AND YOUTH CPS Podcast

Act 16 and Medical Cannabis in Pennsylvania

Medicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system

420 ADVISORY MANAGEMENT

These documents were created to support the work of the Coalition of Colorado Campus Alcohol and Drug Educators. We welcome prevention teams at

Medicinal Cannabis. Patient Log Book. Record your cannabis use and find the right dose

Medical Marijuana. Navigating Medical Marijuana in Workers Compensation

Jan. 12, 2017 FOR IMMEDIATE RELEASE

The ATTC Network LEARNING OBJECTIVES. Clinical Skills in the Era of Legal Cannabis. Clinical Skills in the Era of Legal Cannabis 6/30/2015

I would like to begin by acknowledging that we are on the ancestral grounds of the Beothuk people

PATIENT QUESTIONNAIRE

INTRODUCTION WHAT IS MARIJUANA 2/28/2018

Recent trends in medical cannabis use in Canada

Medical Marijuana. Speaker Disclosure Requirements. Share with a Partner 4/10/2015

Conflicts of interest

DEPARTMENT OF COMMUNITY RESOURCES INTEROFFICE MEMORANDUM

Weeding Through the Science of Cannabis. Ryan Vandrey, PhD

WHO Expert Committee on Drug Dependence Pre-Review: Cannabis plant and resin. Expert Peer Review 2

Quick Internal Medicine Topics

Questionnaire 1 of 5: Cannabis Plant and Cannabis Resin. Introduction

The Effects known & unknown of Marijuana in Older Adults. Danielle Fixen, PharmD, BCGP, BCPS University of Colorado School of Pharmacy

Is the most common illicit drug used in the United States. After a period of decline in the last decade, its use has been increasing among young

Cannabidiol, or CBD, Benefits for Pain, Mental Illness & Anxiety

Cannabis for Medical Use: Body and Mind

MARIJUANA: Selected Effects on Brain, Body & Behavior

2018/05/01 DISCLOSURE EFFECTS OF CANNABIS USE IN ADOLESCENTS

RECREATIONAL CANNABIS LEGALIZATION IN ONTARIO

Medical Marijuana Myths and Realities

Medical Cannabis use in the Older Patient. Amanjot Sidhu, MD, FRCPC Division of Geriatric Medicine McMaster University

PATIENT QUESTIONNAIRE

Proposal 18-1: Marijuana Legalization

Many drugs of abuse are illegal drugs. Possessing, using, buying, or selling these drugs is illegal for people of any age.

Marijuana Legalization 2016: Understanding the policy landscape and design considerations

MEDICAL CANNABIS IN MINNESOTA

Cannabis. Member of the Cannabaceae family of flowering plants (along with hops) Cannabis sativa (v. sativa, indica, afghanica, ruderalis)

Transcription:

Marijuana DATE: June 26, 2018 PRESENTED BY: Melissa Weimer, DO, MCR, FASAM

Disclosures Speaker: Melissa Weimer, DO, MCR, has nothing to disclose. Planning Committee: The members of the planning committee (Jessica Gregg, Todd Korthuis, Melissa Weimer, John Mahan, Laura Heesacker, O Nesha Cochran, and Chris Colasurdo) have nothing to disclose. Dr. Korthuis serves as principal investigator for NIH-funded research that accepts donated extended-release naltrexone (Alkermes) and buprenorphine/naloxone (Indivior). 2 2

Objectives Describe marijuana laws in the state of Oregon and the nation List evidence available for medicinal use of marijuana Describe risks associated with marijuana use, particularly in adolescents 3 3

Percentage of past month marijuana use among persons aged >12 years, by sex National Survey on Drug Use and Health, US 2002-2014 male female -35% increase in past month use of marijuana since 2002-92% increase in daily or almost daily use since 2002 -decreased perceived risk of marijuana use MMWR, 2016, #65 Hasin, 2015

* * http://www.businessinsider.com/ where-is-marijuana-legal-2016-11

2014 Oregon Measure 91 You can possess and use recreational marijuana if you are 21 +. If you are younger, it is illegal. You can use recreational marijuana at home or on private property, including edibles. You can possess up to 8 oz (454 joints) of usable marijuana in your home Medical Marijuana can possess 24 oz (1360 joints) You can possess up to 1 oz of marijuana outside of your home You can grow up to 4 plants per residence, out of public view Approved medical dispensaries may sell small amounts of marijuana to recreational users You can t take marijuana across state lines, including WA www.whatslegaloregon.com

Cannabis raw materials marijuana (up to 20%+ THC) marijuana concentrate (40-80%) budder, butane honey oil hashish (~2-20%) hash oil, marijuana concentrate (40-80%) cannabidiol oil Photo Source: www.dea.gov and cureepilepsy.org

Marijuana is the beer of THC, as dabbing is to vodka.

What s actually in that marijuana you are buying? Δ 9 -tetrahydrocannabinol (THC) Euphoria (reward pathway) Psychosis Antiemetic Appetite stimulant Analgesic Impairs judgement Cognitive impairment Reduced coordination and balance Tachycardia Cannabidiol (CBD) Analgesic Antianxiety Antipsychotic effects Anti-inflammatory Anti-seizure Anti-spasmodic Neuroprotective Bradycardia Most marijuana labels are incorrect. Vandrey, JAMA, 2015 found 23% under-labeled, 60% over-labeled, 17% accurately labeled

Clinical Questions What does the evidence tell us about the effectiveness of marijuana for chronic pain?

VA Evidence-based Synthesis Program, Kansagara, et al., 2016 What are the effects of cannabis on health outcomes and healthcare utilization for adults who have chronic pain? 2 Systematic Reviews, 5 RCTs, 3 Observational studies Summary: Limited evidence with few rigorous trials and methodologic flaws Low strength evidence that cannabis with precise THC:CBD content (1:1 to 2:1 ratio) has potential to improve pain, spasticity, and sleep in select population with multiple sclerosis and neuropathic pain Most studies short term (<14 days), long-term benefits and harms unclear 8 trials (N=1370) found non-significant trend toward 30% reduction in pain (OR = 1.41 (95% confidence interval [CI] = 0.99-2.00) compared to placebo and no difference in quality of life among groups Insufficient evidence for medicinal use for cancer, RA, and MSK pain https://www.hsrd.research.va.gov/publications/esp/cannabis-exec.pdf

Population: Adults with chronic pain and lack of analgesia with at least 2 analgesics from 2 different classes at full dose MSK pain, neuropathic pain, radicular LBP Major exclusions: pts with drug abuse or dependence or at high risk for drug abuse or history of psychiatric comorbidity Primary outcome: Pain reduction after 6 months Dose of cannabis 20g/month (~3-4:1 THC:CBD) 1g joint (6-14% THC; 0.2-3.8% CBD), baked cookies (11-19% THC; 0.5-5.5% CBC), or olive oil extract drops Titrate dose for effect, up to TID ITT 206 patients, mean follow up 7 months Haroutounian, et al. Clin J Pain, Volume 32, No 12, December 2016

Haroutounian, et al, 2016 Avg use was 43.2 g/month Primary Outcome: Pain Symptom score improved from 83 to 75 (p<0.001) Secondary Outcomes: -family-social disability improved -role-emotional disability improved -satisfaction with outcome improved -mixed results for functional improvements 5% discontinued due to side effects

Opioid Discontinuation Outcome 44-48% reduction from baseline (p<0.001) MED changed 60mg to 45mg (p=0.19) 80 70 60 50 40 30 20 10 0 N=83 N = 43 Opioid Therapy Discontinued opioid therapy Haroutounian, et al. Clin J Pain, Volume 32, No 12, December 2016

Practical Issues/Questions Half life 25-36 hrs, but analgesic effect only 3-4 hours How do you determine the dose? How do you ensure consistency in the product? What happens when you develop tolerance? What if your work will not allow it? Esther Choo, MD, MPH, Sarah Feldstein-Ewing, PhD, Travis Lovejoy, PhD, MPH

Clinical Questions What are some clear harms of marijuana?

Adverse Effects: Short-term anxiety, panic attacks psychosis increased heart rate and blood pressure decreased memory & learning difficulty thinking & problem solving decreased coordination Increased risk of MVA if driving visuomotor skills deficit *Effects transient, resolve without intervention.* *Actual impairment persists past perceived impairment* *Effects primarily associated with THC*

No one has died from a marijuana overdose, although some people have ingested way too much and wished they were dead or thought they were dying.

Adverse Effects: Long-term associated with Altered brain development and neural connectivity Reduced memory Reduced learning Reduced impulse control Worsen mental illness Immunosuppression Inhalation: increased risk cancer of head, neck, lungs, respiratory tract Increased risk testicular cancer Occlusion brain arteries, increased stroke Oculomotor control deficit Hyperemesis syndrome

Marijuana effects on Children and Adolescents* Impaired neural connectivity in specific brain regions Particularly in areas of alertness, learning and memory Declined IQ Altered reward pathways Exacerbation of mental illness Increased risk of cannabis use disorder 2-4 times more likely to develop CUD within 2 years of first use Prenatal exposure effects can also be long lasting (Hanan, Biological Psychiatry, 2016) *through age 21 Volkow, NEJM, June 5, 2014.

Cannabis Withdrawal Syndrome Sudden discontinuation generally safe, no need to taper Withdrawal syndrome: -fatigue -low energy -depression, dysphoria -anxiety -insomnia -decreased appetite -nausea and vomiting No pharmacologic intervention needed (nor effective) for withdrawal Do not use Dronabinol to help with marijuana replacement therapy

Summary and other Key Points Useful in cachexia, MS spasticity, nausea and vomiting from chemotherapy Beware of the narrow therapeutic window Trial of high CBD content (low THC) marijuana for pain Most appropriate in a patient with low risk Do not drive and use marijuana Uncertain effects of concomitant opioids and marijuana Recommend choosing either opioids or marijuana for chronic non-cancer pain Marijuana can have permanent adverse effects on children and adolescents Avoid marijuana use in pregnancy and while breastfeeding until further research is done

Slide attributed to Nora Volkow, Director of NIDA, Marijuana s effects on brain, body, and behavior

Addiction Treatment Options No medication-assisted treatment needed (nor effective) for cannabis use disorder in adults N-Acetylcysteine 1,200mg BID + contingency management was effective in adolescents* Marijuana Use Disorder Treatment: Cognitive Behavioral Therapy (CBT) recovery groups (Marijuana Anonymous) *Gray, K. M., et al. (2012), A double-blind randomized controlled trial of N-Acetylcysteine (NAC) in Cannabis-Dependent Adolescents. The American Journal of Psychiatry, 8: 805-812.

Slide attributed to Nora Volkow, Director of NIDA, Marijuana s effects on brain, body, and behavior

Oregon Marijuana Law 1935 Uniform State Narcotic Drug Act made marijuana illegal 1973 The Oregon Decriminalization Bill Abolished criminal penalties for possession of a small amount of marijuana 1998 Measure 67 - Oregon Medical Marijuana Act Can have up to 1.5 pounds of marijuana at a time 2010 Oregon Board of pharmacy reclassifies marijuana from Schedule I to Schedule II Federal maintains that marijuana is Schedule I 2014 - Measure 91 - Recreational use of marijuana legalized 2015 - Senate Bill 844 requires the Oregon Health Authority to establish a task force to study the medical and public health properties of cannabis

Cannabis concentration and serving size limits based on indication Medical Marijuana Recreational Marijuana Type of Marijuana Item Maximum Concentration or amount of THC per serving Maximum Concentration or Amount of THC in container Maximum Concentration or amount of THC per serving Maximum Concentration or Amount of THC in container Edible N/A 100mg 5mg 50mg Topical N/A 6% N/A 6% Tincture N/A 4,000mg N/A 1,000mg Capsule 100mg 4,000mg 10mg 100mg Concentrate or Extract N/A 4,000mg N/A 1,000mg Other N/A 4,000mg N/A 1,000mg U.S.-grown marijuana, in its present form, is many time stronger than in the past. http://public.health.oregon.gov/diseasesconditions/chronicdisease/medicalmarijuanaprogram/pages/legal.aspx

How much is too much? Standard marijuana cigarette or joint = 0.5g marijuana 1-2 joint/day = 0.5 to 1 oz of marijuana per month 24 oz of marijuana = 680 g of marijuana 1360 marijuana joints 8 oz of marijuana = 227 g of marijuana 454 marijuana joints 1 oz of marijuana = 28 g of marijuana 14 marijuana joints Is marijuana policy ahead of the science? Programme of Substance Abuse. Cannabis: A Health Perspective and Research Agenda. Geneva, Switzerland: WHO; 1997.

Regular Marijuana Use Is Associated With Differences in Brain Gray Matter and Connectivity Filbey, F.M.; Aslan, S.; Calhoun, V.D.; et al. Long-term effects of marijuana use on the brain. Proceedings of the National Academy of Sciences 111(47):16913-16918, 2014